The Current and Future State of Immune Checkpoint Inhibitors in NSCLC

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

A brief review of AEs seen with immunotherapy in advanced non–small cell lung cancer followed by advice on how to nuance safety data in this setting.

Shared insight on the optimal selection and use of single-agent immunotherapy guided by the testing and expression of PD-L1.

Shifting their focus to chemoimmunotherapy combinations in advanced NSCLC, experts review clinical trial data from KEYNOTE-189, IMpower150, and EMPOWER-Lung 3.

A brief discussion on when it is appropriate to discontinue chemoimmunotherapy in patients with advanced non–small cell lung cancer.

Expert perspectives on the CheckMate 227 clinical trial, which combined ipilimumab and nivolumab IO therapy in patients with advanced NSCLC.

Shared insight on the CheckMate 9LA trial, which combined dual IO therapy with chemotherapy in the setting of advanced non–small cell lung cancer.

Closing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.